MX2018011813A - Medicina obtenida mediante la combinacion de agonista fxr y arb. - Google Patents

Medicina obtenida mediante la combinacion de agonista fxr y arb.

Info

Publication number
MX2018011813A
MX2018011813A MX2018011813A MX2018011813A MX2018011813A MX 2018011813 A MX2018011813 A MX 2018011813A MX 2018011813 A MX2018011813 A MX 2018011813A MX 2018011813 A MX2018011813 A MX 2018011813A MX 2018011813 A MX2018011813 A MX 2018011813A
Authority
MX
Mexico
Prior art keywords
arb
combining
fxr agonist
medicine obtained
pharmaceutically acceptable
Prior art date
Application number
MX2018011813A
Other languages
English (en)
Inventor
Namisaki Tadashi
Yoshiji Hitoshi
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MX2018011813A publication Critical patent/MX2018011813A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención proporciona un agente terapéutico para NASH que incluye: un agonista de FXR, preferiblemente ácido obeticólico o una sal farmacéuticamente aceptable del mismo; y un ARB o una sal farmacéuticamente aceptable del mismo.
MX2018011813A 2016-03-28 2017-03-27 Medicina obtenida mediante la combinacion de agonista fxr y arb. MX2018011813A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016064475 2016-03-28
PCT/JP2017/012448 WO2017170434A1 (ja) 2016-03-28 2017-03-27 Ｆｘｒアゴニストとａｒｂの組み合わせ医薬

Publications (1)

Publication Number Publication Date
MX2018011813A true MX2018011813A (es) 2019-01-24

Family

ID=59965591

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011813A MX2018011813A (es) 2016-03-28 2017-03-27 Medicina obtenida mediante la combinacion de agonista fxr y arb.

Country Status (17)

Country Link
US (1) US11419878B2 (es)
EP (1) EP3437659B1 (es)
JP (1) JPWO2017170434A1 (es)
KR (1) KR20180124123A (es)
CN (1) CN109152840A (es)
AU (1) AU2017241559A1 (es)
BR (1) BR112018069789A2 (es)
CA (1) CA3019496A1 (es)
CL (1) CL2018002727A1 (es)
EA (1) EA037330B1 (es)
IL (1) IL262057A (es)
MX (1) MX2018011813A (es)
PH (1) PH12018502109A1 (es)
SG (1) SG11201808607SA (es)
TW (1) TW201733582A (es)
UA (1) UA124499C2 (es)
WO (1) WO2017170434A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022508402A (ja) * 2018-08-30 2022-01-19 ターンズ・ファーマシューティカルズ・インコーポレイテッド 肝障害の治療
MX2021005316A (es) * 2018-11-08 2021-09-10 Intercept Pharmaceuticals Inc Métodos de uso del ácido obeticólico.
DE102019108825A1 (de) * 2019-04-04 2020-10-08 Eberhard Karls Universität Tübingen Medizinische Fakultät Verbindungen und Verfahren zur Behandlung von Erkrankungen der Leber
KR20210020788A (ko) 2019-08-14 2021-02-24 주식회사 바이오톡스텍 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물
EP4054567A4 (en) * 2019-11-08 2024-01-10 Terns Pharmaceuticals Inc TREATMENT OF LIVER DISEASES
WO2021133948A1 (en) * 2019-12-23 2021-07-01 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders
BR112022022952A2 (pt) * 2020-05-13 2023-01-10 Terns Pharmaceuticals Inc Tratamento combinado de distúrbios hepáticos
WO2022046779A1 (en) 2020-08-25 2022-03-03 Eli Lilly And Company Polymorphs of an ssao inhibitor
KR20230043773A (ko) 2021-09-24 2023-03-31 (주)샤페론 염증복합체 억제제를 유효성분으로 함유하는, 비알코올성 지방간염, 간 섬유화의 예방, 개선 또는 치료용 약학적 조성물
KR20230052237A (ko) 2021-10-12 2023-04-19 (주)샤페론 타우로데옥시콜산 신규 제제
WO2023140350A1 (ja) * 2022-01-21 2023-07-27 国立大学法人 長崎大学 臓器の線維化抑制用医薬組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138390B2 (en) 2001-03-12 2006-11-21 Intercept Pharmaceuticals Steroids as agonists for FXR
JP5094384B2 (ja) 2004-03-12 2012-12-12 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｆｘｒリガンドを使用する線維症の処置
JP5222846B2 (ja) 2006-06-27 2013-06-26 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｆｘｒ媒介疾患または状態の予防または治療のためのｆｘｒリガンドとしての胆汁酸誘導体
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US9238673B2 (en) 2012-06-19 2016-01-19 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
CN105592846A (zh) * 2013-03-15 2016-05-18 持田制药株式会社 用于治疗非酒精性脂肪性肝炎的组合物和方法
MX2015011466A (es) * 2013-03-15 2016-01-22 Boehringer Ingelheim Int Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
MX2015017035A (es) * 2013-06-13 2016-04-25 Fast Forward Pharmaceuticals B V Inhibidor de la señalizacion de cd40 y un compuesto adicional, en donde el compuesto adicional es un acido labil, un derivado de acido labil, un agonista del receptor tgr5, un agonista del fxr o una combinacion de los mismos, para el tratamiento de inflamacion cronica, y la prevencion de cancer gastrointestinal o fibrosis.
EP3023098B1 (en) * 2013-07-18 2020-06-24 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of omega-3 fatty acid
CN105175473B (zh) * 2015-08-19 2018-12-21 丽珠医药集团股份有限公司 一种奥贝胆酸晶型i及其制备方法、药物组合物和用途

Also Published As

Publication number Publication date
EA201892119A1 (ru) 2019-02-28
UA124499C2 (uk) 2021-09-29
KR20180124123A (ko) 2018-11-20
WO2017170434A1 (ja) 2017-10-05
EP3437659A1 (en) 2019-02-06
TW201733582A (zh) 2017-10-01
EA037330B1 (ru) 2021-03-12
CA3019496A1 (en) 2017-10-05
BR112018069789A2 (pt) 2019-01-29
SG11201808607SA (en) 2018-11-29
IL262057A (en) 2018-11-29
US20190247404A1 (en) 2019-08-15
EP3437659B1 (en) 2023-03-01
JPWO2017170434A1 (ja) 2019-01-31
EP3437659A4 (en) 2019-12-11
CL2018002727A1 (es) 2018-12-07
CN109152840A (zh) 2019-01-04
AU2017241559A1 (en) 2018-11-01
US11419878B2 (en) 2022-08-23
PH12018502109A1 (en) 2019-09-23

Similar Documents

Publication Publication Date Title
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
JOP20200230A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
MX2021006901A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12016501841A1 (en) Immunosuppressant formulation
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2016014946A (es) Derivados de carboxamida.
MX2020012989A (es) Agente terapeutico para la fibrosis.
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
IN2014MU00043A (es)
EA038580B9 (ru) Агонист fxr, представляющий собой производное стероидов
PH12016502247A1 (en) Carboxamide derivatives
MX2018002193A (es) Metodo de uso de quinoxalinilo-piperazinamida.
IN2014DE00822A (es)